Pharmaceutics and diagnostics
In the past 150 years, we have seen tremendous advances in pharmacology and medicine in general, such as the discovery of antibiotics, widespread adoption of vaccines, and many more. As a result, the average life expectancy in the world has more than doubled since the 1900s.

The problem is that we cannot measure biological age easily, as it is not the same as one's chronological age. This makes it difficult to assess life extension treatment efficacy without having to invest in lifelong longitudinal studies. Possible solutions could be ageing clocks based on walking speed, change in Resting Heart Rate, etc.
Ageing process simulation
Development of an in silico ageing model to simulate the ageing process based on open datasets and probably some form of a generative or even a mechanistic model. This could be related to clinical measurements, or maybe to some molecular features, like gene expression, etc.

A complication with medications is their secondary effect, so-called polypharmacy. Think of harnessing currently existing medications, or their combinations, for repurposing in life extension. A possible way to do this is to enable collecting and organizing grassroots trials for mTOR inhibitors (rapalogs), statins, metformin, etc., as these seem to increase lifespan and healthspan in model organisms.
Patient risks' assessment
To assess patients' risk, one could develop an open-source platform or possibly a custom software for hospitals. For example, using nomograms, one could combine several diagnostic results into an easy-to-understand 1-5 / 0-1 / 0-100 risk scale.

Data sharing
By creating a platform, we could enable physicians worldwide to share anonymized data about the efficacy of treatments versus diseases.
Made on